Studies in mouse models of CRC [84] and cell lines [85] showed that IL-17 inhibits the recruitment of CD8+ T cells and increased PDL1 expression, thereby promoting resistance to anti-PD1 therapy. Here, IL17A is linked to colorectal carcinoma.